University Hospitals Leicester
Welcome,         Profile    Billing    Logout  
 9 Trials 
26 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Samani, Nilesh
NCT04388943: Biomedical Research Informatics Centre for Cardiovascular Sciences (The BRICCS Study)

Recruiting
N/A
9500
Europe
Observation
University Hospitals, Leicester, University of Leicester
Cardiovascular Diseases, Cardiovascular Risk Factor
03/27
03/27
GENVASC, NCT04417387: The Genetics and Vascular Health Check Study () Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)

Recruiting
N/A
30000
Europe
Observational
University of Leicester, University Hospitals, Leicester
Cardiovascular Diseases
03/27
03/27
Fennell, Dean A
CONFIRM, NCT03063450 / 2016-003111-35: CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma

Active, not recruiting
3
332
Europe
Nivolumab, Opdivo, Placebo
University of Southampton, Bristol-Myers Squibb
Mesothelioma
02/23
02/23
DENIM, NCT03610360 / 2017-001774-41: DENdritic Cell Immunotherapy for Mesothelioma

Completed
2/3
176
Europe
MesoPher
Amphera BV, TMC Pharma
Mesothelioma
06/22
06/22
MiST, NCT03654833 / 2017-003353-41: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
NERO, NCT05455424: Niraparib Efficacy in Patient With Unresectable Mesothelioma

Active, not recruiting
2
88
Europe
Niraparib Oral Product, Zejula, Active Symptom Control
University Hospital Southampton NHS Foundation Trust, University of Southampton, British Lung Foundation
Mesothelioma, Malignant
12/24
12/24
MITOPE, NCT05278975: Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma

Recruiting
1/2
186
Europe
RSO-021, Thiostrepton
RS Oncology LLC
Malignant Pleural Effusion, Malignant Pleural Mesothelioma, Mesothelioma, Mesotheliomas Pleural, Mesothelioma; Lung, Pleural Effusion, Malignant
04/25
04/25
NCT05228015: Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

Terminated
1
67
Europe, US, RoW
IK-930, Osimertinib
Ikena Oncology
Solid Tumors, Adult, Solid Tumor, Malignant Pleural Mesothelioma (MPM), Epithelioid Hemangioendothelioma (EHE), NF2 Deficient Mesothelioma, Other NF2 Deficient Solid Tumors and Solid Tumors with YAP1/TAZ Fusion Genes, NF2 Deficiency, YAP1 or TAZ Gene Fusions
08/24
09/24
TRACERx, NCT01888601: TRAcking Non-small Cell Lung Cancer Evolution Through Therapy (Rx)

Active, not recruiting
N/A
814
Europe
University College, London, Cancer Research UK
Non-small Cell Lung Cancer
12/26
12/26
Kaushik, Monika
BIOSYM, NCT05449691: Biological Matrices Versus Synthetic Meshes

Recruiting
N/A
60
Europe
One-stage immediate breast reconstruction
University Hospitals of Derby and Burton NHS Foundation Trust
Breast Cancer
04/26
04/26
ATNEC, NCT04109079: Axillary Management in Breast Cancer Patients with Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy

Recruiting
N/A
1900
Europe
Axillary lymph node dissection, Axillary radiotherapy, Breast or chest wall radiotherapy
University Hospitals of Derby and Burton NHS Foundation Trust
Breast Cancer, Sentinel Lymph Node, Neoplasm, Breast
02/30
02/30
Bomalaski, John S
NCT05317819: Study of ADI-PEG 20 Versus Placebo in Subjects with High Arginine Level and Unresectable Hepatocellular Carcinoma

Recruiting
3
300
RoW
ADI-PEG20, pegargiminase, Placebo
Polaris Group
Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
09/25
10/25
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
NCT05842512: Study of ADI-PEG 20 Versus Placebo in Subjects With NASH

Recruiting
2
40
RoW
ADI-PEG20, Pegargiminase, Placebo
Polaris Group
Nonalcoholic Steatohepatitis (NASH)
12/27
01/28
POLARIS2020-002, NCT05001828: Study of ADI-PEG 20, Venetoclax and Azacitidine in Acute Myeloid Leukemia

Recruiting
1
60
US
ADI-PEG 20, Venetoclax, Azacitidine
Polaris Group
Acute Myeloid Leukemia, Adult
07/25
12/25
Bown, Matt J
LIMb, NCT04027244: Leg Ischaemia Management Collaboration

Recruiting
N/A
420
Europe
University of Leicester, University Hospitals, Leicester, National Institute for Health Research, United Kingdom, The George Davies Charitable Trust
Peripheral Arterial Disease, Critical Limb Ischemia, Frailty, Cognitive Impairment, Coronary Artery Disease
05/22
05/31
NCT06047002: Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease

Recruiting
N/A
150
Europe
University of Leicester
Peripheral Arterial Disease
12/24
12/24
Beeston, Emma P
NCT04388943: Biomedical Research Informatics Centre for Cardiovascular Sciences (The BRICCS Study)

Recruiting
N/A
9500
Europe
Observation
University Hospitals, Leicester, University of Leicester
Cardiovascular Diseases, Cardiovascular Risk Factor
03/27
03/27
GENVASC, NCT04417387: The Genetics and Vascular Health Check Study () Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)

Recruiting
N/A
30000
Europe
Observational
University of Leicester, University Hospitals, Leicester
Cardiovascular Diseases
03/27
03/27
Fawke, Joe
POLAR, NCT04372953 / ACTRN12618001686291: Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The Trial).

Recruiting
N/A
906
Europe, US, RoW
Positive End-Expiratory Pressure (PEEP)
Murdoch Childrens Research Institute, University of Pennsylvania, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University of Oxford
Lung Injury, Preterm Birth
11/26
05/28
Matar, Maz
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
Roopun, Rehanah
DELIVER-MS, NCT03535298: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Active, not recruiting
4
800
Europe, US
Early Highly Effective Therapies Group, Lemtrada (alemtuzumab), Ocrevus (ocrelizumab), Tysabri (natalizumab), Rituxan (rituximab), Kesimpta (ofatumumab), Briumvi (ublituximab), Escalation Therapies Group, Betaseron (beta interferon), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Extavia (beta interferon), Gilenya (fingolimod), Glatopa (glatiramer acetate), Plegridy (beta interferon), Rebif (beta interferon), Tecfidera (dimethyl fumarate), Avonex (beta interferon), Mavenclad (cladribine), Mayzent (siponimod), Vumerity (diroximel fumarate), Zeposia (ozanimod), Bafiertam (monomethyl fumarate), Ponvory (ponesimod)
The Cleveland Clinic, University of Nottingham
Multiple Sclerosis, Relapsing-Remitting
07/27
09/30
Mughal, Kamaal
POLAR, NCT04372953 / ACTRN12618001686291: Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The Trial).

Recruiting
N/A
906
Europe, US, RoW
Positive End-Expiratory Pressure (PEEP)
Murdoch Childrens Research Institute, University of Pennsylvania, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University of Oxford
Lung Injury, Preterm Birth
11/26
05/28
Messeder, Sarah Jane
NCT06047002: Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease

Recruiting
N/A
150
Europe
University of Leicester
Peripheral Arterial Disease
12/24
12/24
Abraham, Niranjan
POLAR, NCT04372953 / ACTRN12618001686291: Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The Trial).

Recruiting
N/A
906
Europe, US, RoW
Positive End-Expiratory Pressure (PEEP)
Murdoch Childrens Research Institute, University of Pennsylvania, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University of Oxford
Lung Injury, Preterm Birth
11/26
05/28
Blochlinger, Georgina
POLAR, NCT04372953 / ACTRN12618001686291: Positive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The Trial).

Recruiting
N/A
906
Europe, US, RoW
Positive End-Expiratory Pressure (PEEP)
Murdoch Childrens Research Institute, University of Pennsylvania, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), University of Oxford
Lung Injury, Preterm Birth
11/26
05/28

Download Options